NMRA · Neumora Therapeutics, Inc.
$1.61
+0.01 (+0.63%)
At close · Jul 17
Market Cap
$298.31M
Shares
185,284,244
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$236.93M
+2.8%
FY2025
Diluted EPS
-$1.45
+5.2%
FY2025
Operating Cash Flow
-$206.44M
-12.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $162.51M | $176.07M | $200.93M | $142.72M | |
| $55.57M | $60.09M | $62.54M | $45.48M | |
| — | $208K | $631K | $668K | |
| $223.08M | $241.16M | $263.46M | $252.1M | |
| -$223.08M | -$241.16M | -$263.46M | -$252.1M | |
| — | $2.01M | — | — | |
| — | $8.34M | — | — | |
| $745K | $4.36M | $19.86M | $16.44M | |
| — | — | — | $18K | |
| -$222.34M | -$236.8M | -$243.61M | -$235.66M | |
| $55K | $130K | $178K | $268K | |
| -$222.39M | -$236.93M | -$243.79M | -$235.93M | |
| -$222.39M | -$236.99M | -$243.65M | -$235.23M | |
| USD/shares | — | -$1.45 | -$1.53 | -$3.63 |
| USD/shares | — | -$1.45 | -$1.53 | -$3.63 |
| shares | — | 163.39M | 159.38M | 65.02M |
| shares | — | 163.39M | 159.38M | 65.02M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.75×
EV/EBIT
—
Biotechnology median 26.36×
P/E (TTM)
—
Biotechnology median 7.37×